Twist Bioscience CORP Form 4 insider transactions

Paula Green, SVP of Human Resources at Twist Bioscience, executed a non-discretionary sale of 619 common shares to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's CFO, Adam Laponis, sold 918 shares of common stock for $25.964 per share to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 1,840 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

A Twist Bioscience executive sold 521 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience director Katryn Blake received a restricted stock unit award of 14,353 shares, vesting over three years.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 186 shares of common stock to cover tax withholding obligations related to RSU vesting.

Emily M. Leproust, CEO of Twist Bioscience, sold 5,585 shares to cover tax obligations related to vesting Restricted Stock Units.

Twist Bioscience's SVP of Human Resources sold 1,255 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Twist Bioscience's Chief Legal Officer, Dennis Cho, reported a pre-planned sale of 785 common shares at $28.364 per share, scheduled for August 4, 2025, to cover tax obligations from restricted stock unit vesting.

Twist Bioscience Corporation's President and COO, Patrick John Finn, sold 3,189 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,232 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,449 shares of common stock at $38.146 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 125 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience Corp, sold 209 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Twist Bioscience CEO Emily M. Leproust sold 476 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation, sold 142 shares of common stock to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units.

Twist Bioscience Corporation's CEO, Emily M. Leproust, reported a non-discretionary sale of 1,678 common shares to satisfy tax withholding obligations related to vested Restricted Stock Units.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp., executed a non-discretionary sale of 292 common stock shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 230 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 94 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp., sold 257 shares of common stock for tax withholding purposes related to Restricted Stock Unit vesting.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 853 shares of common stock on June 6, 2025, at $31.75 per share to satisfy tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience CEO Emily M. Leproust sold 2,170 shares of common stock on June 6, 2025, at $31.75 per share, solely to satisfy tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, sold 225 shares of common stock at $31.75 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Twist Bioscience Corp.'s Chief Accounting Officer, Robert F. Werner, sold 839 shares of common stock for $27.728 per share to satisfy tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience Corporation's CEO, Emily M. Leproust, sold 2,802 shares of common stock at $29.747 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 531 shares of common stock to satisfy tax withholding obligations related to vested restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 632 shares of common stock at $29.747 per share to satisfy tax withholding obligations related to Restricted Stock Unit vesting.

Patrick John Finn, President and COO of Twist Bioscience Corp., sold 1,877 shares of common stock at $29.747 per share to cover tax withholding obligations related to Restricted Stock Units vesting, a non-discretionary transaction.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 242 shares of common stock for $29.747 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.